Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma

作者：Caroline Robert, Bogusława Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Maćkiewicz, Daniil Stroyakovskiy, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion‐Sileni, Kamil Drucis, Ivana Krajsová, Axel Hauschild, Bijoyesh Mookerjee, Jeffery J. Legos, Y. Zhang, Stephen Lane, Dirk Schadendorf · 发表于：Annals of Oncology · 年份：2016 · DOI：10.1093/annonc/mdw435.37 · 被引用次数：74 · 研究领域：Melanoma and MAPK Pathways、CAR-T cell therapy research、Cutaneous Melanoma Detection and Management